SARS‐CoV2 disease seen through the prism of acutely decompensated chronic kidney disease and ischemic stroke: What lesson we have learned from using prophylaxis therapy of vascular thromboembolism?

• Published in: Clinical case reports Vol. 8; no. 12; pp. 3229 - 3233
• Main Authors: Hazim, Asmaa, Aasfara, Jehanne, Slassi, Ilham, Canaud, Bernard, Haoudar, Amal, Naitlhou, Abdelhamid, El Kettani, Chafik
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.12.2020; John Wiley and Sons Inc; Wiley
• Subjects: acute kidney injury; Anticoagulants; Atherosclerosis; Case Report; Case Reports; Cerebrovascular disease; chronic kidney disease; Consciousness; Coronaviruses; COVID-19; Disease prevention; Dyspnea; Hemodialysis; Hemoglobin; Hypertension; Hypoxia; Infections; Inflammation; ischemic stroke; Kidney diseases; Medical imaging; Molecular weight; Patients; Pneumonia; Risk factors; SARS‐CoV2; Sepsis; Severe acute respiratory syndrome coronavirus 2; Stroke; Thromboembolism; Thrombosis; vascular thromboembolism anticoagulation; chronic kidney disease; acute kidney injury; vascular thromboembolism anticoagulation; SARS‐CoV2; ischemic stroke
• ISSN: 2050-0904; 2050-0904
• DOI: 10.1002/ccr3.3385

Our case underlines the tight management of antithrombotic therapy in the context of acutely decompensated chronic kidney disease, ischemic stroke, and SARS‐CoV2 infection, the development of stroke as a SARS‐CoV2 complication increase the chances of adverse outcomes that may be mitigated by a rapid recognition and institution of available treatments. Our case underlines the tight management of antithrombotic therapy in the context of acutely decompensated chronic kidney disease, ischemic stroke, and SARS‐CoV2 infection, the development of stroke as a SARS‐CoV2 complication increase the chances of adverse outcomes that may be mitigated by a rapid recognition and institution of available treatments.